Journal of Vascular and Interventional Radiology最新文献

英文中文

Crossword Puzzle 纵横字谜游戏

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.107914

引用次数: 0

Cryoablation Protocols for Primary and Metastatic Lung Tumors: A Systematic Review and Meta-Analysis Evaluating Effectiveness and Safety of Percutaneous Cryoablation of Pulmonary Tumors 原发性和转移性肺肿瘤的冷冻消融方案：一项评估经皮肺肿瘤冷冻消融有效性和安全性的系统综述和荟萃分析。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.004

Arman Sarshoghi , Arash Sarshoghi MSc , Maxime Têtu MSc , Calvin S.H. Ng MD , Lonny Yarmus DO , Patrick Bourgouin MD , Stephen B. Solomon MD , Felix Herth MD, PhD , Robert P. Liddell MD , Moishe Liberman MD, PhD

Purpose

To evaluate 1-year local tumor control (LTC) after percutaneous cryoablation for lung tumors and to identify procedural protocol and patient/tumor characteristics associated with improved outcomes.

Materials and Methods

A systematic search of PubMed, Embase, and Web of Science was conducted. The primary outcome was LTC at 1 year. Secondary outcomes included the identification of factors associated with LTC and pooled adverse event rates, such as freezing lengths, number of cycles, tumor characteristics, and more. Data were pooled using a random-effects model, and meta-regression was used to analyze factors affecting LTC.

Results

Nineteen studies (786 patients, 1,048 tumors) yielded a pooled 1-year LTC of 90.5% (95% CI, 85.1%–94.1%). Multivariate meta-regression showed that smaller tumor size was significantly associated with improved LTC. Univariate analysis also identified that superior LTC was associated with a triple freeze-thaw protocols (vs double), a shorter first freeze duration, a longer final freeze duration, and ending the procedure with a thaw cycle. The incidence of adverse events (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥3) was 4.9% (95% CI, 2.9%–6.9%), with pneumothorax most common (28% of cases).

Conclusions

Percutaneous cryoablation demonstrates high effectiveness for lung tumor control. Superior 1-year LTC is associated with smaller tumor size and a triple freeze-thaw protocol characterized by a short initial freeze followed by longer subsequent freezes. These findings provide a data-driven basis for standardizing cryoablation techniques.

目的：本系统综述和荟萃分析旨在评估经皮肺肿瘤冷冻消融后1年的局部肿瘤控制（LTC），并确定与改善预后相关的手术方案和患者/肿瘤特征。方法：系统检索PubMed、EMBASE和Web of Science。主要终点为1年LTC。次要结局包括确定与LTC和汇总不良事件发生率相关的因素，如冷冻时间、周期数、肿瘤特征等。采用随机效应模型对数据进行汇总，并采用元回归分析影响LTC的因素。结果：19项研究（786例患者，1048个肿瘤）得出的1年总LTC为90.5% （95% CI, 85.1%-94.1%）。多变量荟萃回归显示，较小的肿瘤大小与LTC改善显著相关。单变量分析还发现，较好的LTC与三次冻融方案（与两次冻融方案相比）、较短的首次冻融持续时间、较长的最终冻融持续时间以及以解冻周期结束的过程有关。不良事件（CTCAE分级≥3）发生率为4.9% (95% CI: 2.9%-6.9%)，其中气胸最为常见（28%的病例）。结论：经皮冷冻消融治疗肺肿瘤疗效显著。优越的1年LTC与较小的肿瘤大小和三重冻融方案相关，其特征是初始冻结时间短，随后冻结时间长。这些发现为标准化冷冻消融技术提供了数据驱动的基础。

{"title":"Cryoablation Protocols for Primary and Metastatic Lung Tumors: A Systematic Review and Meta-Analysis Evaluating Effectiveness and Safety of Percutaneous Cryoablation of Pulmonary Tumors","authors":"Arman Sarshoghi , Arash Sarshoghi MSc , Maxime Têtu MSc , Calvin S.H. Ng MD , Lonny Yarmus DO , Patrick Bourgouin MD , Stephen B. Solomon MD , Felix Herth MD, PhD , Robert P. Liddell MD , Moishe Liberman MD, PhD","doi":"10.1016/j.jvir.2025.10.004","DOIUrl":"10.1016/j.jvir.2025.10.004","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate 1-year local tumor control (LTC) after percutaneous cryoablation for lung tumors and to identify procedural protocol and patient/tumor characteristics associated with improved outcomes.</div></div><div><h3>Materials and Methods</h3><div>A systematic search of PubMed, Embase, and Web of Science was conducted. The primary outcome was LTC at 1 year. Secondary outcomes included the identification of factors associated with LTC and pooled adverse event rates, such as freezing lengths, number of cycles, tumor characteristics, and more. Data were pooled using a random-effects model, and meta-regression was used to analyze factors affecting LTC.</div></div><div><h3>Results</h3><div>Nineteen studies (786 patients, 1,048 tumors) yielded a pooled 1-year LTC of 90.5% (95% CI, 85.1%–94.1%). Multivariate meta-regression showed that smaller tumor size was significantly associated with improved LTC. Univariate analysis also identified that superior LTC was associated with a triple freeze-thaw protocols (vs double), a shorter first freeze duration, a longer final freeze duration, and ending the procedure with a thaw cycle. The incidence of adverse events (Common Terminology Criteria for Adverse Events [CTCAE] Grade ≥3) was 4.9% (95% CI, 2.9%–6.9%), with pneumothorax most common (28% of cases).</div></div><div><h3>Conclusions</h3><div>Percutaneous cryoablation demonstrates high effectiveness for lung tumor control. Superior 1-year LTC is associated with smaller tumor size and a triple freeze-thaw protocol characterized by a short initial freeze followed by longer subsequent freezes. These findings provide a data-driven basis for standardizing cryoablation techniques.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107871"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Session Ethanol Sclerotherapy for Symptomatic Simple Adrenal Cysts 单期乙醇硬化疗法治疗单纯性肾上腺囊肿。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.008

Peter M. Do BS , James Y. Lim MD , Keith B. Quencer MD , Brian J. Park MD, MS

引用次数: 0

Cover 封面

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/S1051-0443(25)00787-0

引用次数: 0

Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases 肿瘤吸收剂量、代谢反应和乳腺癌肝转移患者放射栓塞后的生存。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.045

Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD

Purpose

To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (⁹⁰Y) transarterial radioembolization (TARE).

Materials and Methods

Between August 2016 and August 2024, patients with BCLM who underwent ⁹⁰Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.

Results

Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (P = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (P = .025 and P = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (P = .024 and P = .397, respectively).

Conclusions

Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.

目的：探讨经动脉放射栓塞（TARE）治疗乳腺癌肝转移（BCLM）患者肿瘤吸收剂量（TAD）与肿瘤反应及生存期的关系。方法与材料：回顾性分析2016年8月至2024年8月间行玻璃颗粒Y90-TARE治疗的BCLM患者。主要结局是总生存期（OS）和肝脏无进展生存期（hPFS）。次要终点为客观有效率。使用实体瘤正电子发射断层扫描反应标准（PERCIST）评估对治疗的反应。患者分为有反应组和无反应组。结果或发现：42例女性中有26例患者符合纳入标准，平均年龄为57.9±13.8岁。所有患者的中位OS和hPFS分别为6.1个月（IQR; 4.3-9.0个月）和4.2个月（IQR; 2.5-5.6个月）。应答者和无应答者的中位TAD分别为157 Gy和150 Gy （p=0.768）。应答者与无应答者的中位OS和hPFS分别为8.3个月（IQR; 5.5-14.8个月）和4.1个月（IQR; 3.1-6.3个月），而4.0个月（IQR; 2.5-4.5个月）和2.1个月（IQR; 1.3-2.7个月），分别为（p= 0.025和p= 0.210）。在145 Gy以上，TAD表现出显著的OS获益，但没有改变肝脏hPFS （p = 0.024和p = 0.397）。结论：在本研究中，影像学反应与OS有一定相关性，而TAD与反应无相关性。

{"title":"Tumor-Absorbed Dose, Metabolic Response, and Survival after Yttrium-90 Radioembolization in Patients with Breast Cancer Liver Metastases","authors":"Osman Melih Topcuoğlu MD , Türkay Toklu , Nalan Alan Selçuk MD , Betül Uzunoğlu MD","doi":"10.1016/j.jvir.2025.08.045","DOIUrl":"10.1016/j.jvir.2025.08.045","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the association between tumor-absorbed dose (TAD) relative to response and survival among patients with breast cancer liver metastasis (BCLM) treated with yttrium-90 (<sup>90</sup>Y) transarterial radioembolization (TARE).</div></div><div><h3>Materials and Methods</h3><div>Between August 2016 and August 2024, patients with BCLM who underwent <sup>90</sup>Y TARE with glass microspheres were retrospectively included. Primary outcomes were overall survival (OS) and hepatic progression–free survival (hPFS). The secondary outcome was the objective response rate. Response to treatment was assessed using Positron Emission Tomography (PET) Response Criteria in Solid Tumors. Patients were divided into 2 groups as responders and nonresponders.</div></div><div><h3>Results</h3><div>Twenty-six women with a mean age of 57.9 years (SD ± 13.8) met the inclusion criteria. The median OS and hPFS for all patients were 6.1 months (interquartile range [IQR], 4.3–9.0 months) and 4.2 months (IQR, 2.5–5.6 months), respectively. The median TAD for responders and nonresponders were 157 Gy and 150 Gy, respectively (<em>P</em> = .768). The median OS and hPFS for responders versus nonresponders were 8.3 months (IQR, 5.5–14.8 months) and 4.1 months (IQR, 3.1–6.3 months) versus 4.0 months (IQR, 2.5–4.5 months) and 2.1 months (IQR, 1.3–2.7 months), respectively (<em>P</em> = .025 and <em>P</em> = .210, respectively). TAD showed a significant OS benefit above 145 Gy but did not change hepatic hPFS (<em>P</em> = .024 and <em>P</em> = .397, respectively).</div></div><div><h3>Conclusions</h3><div>Imaging response was modestly correlated with OS, and TAD was not correlated with response in this series.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107833"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ultrasound Fusion in Interventional Radiology: A Practical Guide to Procedural Applications 介入放射学中的超声融合：程序应用的实用指南。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.016

Benjamin York MD , Bryce D. Beutler MD , Lenora M. Lewis MD , Ellen Y. Chang MD, MS , Ishan Shah BS , April Ballard MD , Brittany J. Kazmierski MD , Samantha S. Chau MD , Hisham Tchelepi MD

Ultrasound (US) fusion, defined as coregistration of cross-sectional images and real-time planar US, has emerged as a powerful tool to enhance the safety and accuracy of image-guided interventions. Computed tomography (CT), magnetic resonance (MR) imaging, and positron emission tomography (PET) can be integrated with conventional US using fusion navigation software, which is available from most major vendors. The US fusion technique enables precise intraprocedural localization of target lesions. The software is broadly accessible, intuitive to use, and suitable for implementation by both interventional and diagnostic radiologists in community and academic settings. In this narrative review, the authors present a comprehensive overview of US fusion–guided interventions, detailing the technical approach and providing case examples from a major teaching hospital.

超声融合被定义为横截面图像和实时平面超声的共同配准，已成为增强图像引导干预的安全性和准确性的有力工具。计算机断层扫描（CT）、磁共振成像（MRI）和正电子发射断层扫描（PET）可以使用融合导航软件与传统超声波集成，这些软件可以从大多数主要供应商那里获得。超声融合技术可以在术中精确定位目标病变。该软件易于访问，使用直观，适合社区和学术环境中的介入和诊断放射科医生实施。在这篇叙述性的综述中，我们提出了超声融合引导干预的全面概述，详细介绍了技术方法，并提供了来自一家大型教学医院的案例。

引用次数: 0

Abernethy Malformation Shunt Closure to Treat Hepatic Encephalopathy Mimicking Parkinson Disease 畸形分流关闭治疗模拟帕金森病肝性脑病。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.043

Rasmiranjan Padhi MBBS, MD , Arun Prasannan MBBS, MD , Virag Shethna MBBS, MD , Jagadeesan Dhanasekaran MBBS, MD , Shanmuga Sundaram Radhakrishnan MBBS, MD

引用次数: 0

Peripheral Vasculature Embolization with the Onyx Liquid Embolic System in a Swine Model 玛瑙液体栓塞系统在猪模型中的外周血管栓塞。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.08.032

Gary P. Siskin MD , Paul J. Rochon MD , Ripal Gandhi MD , Austin Cocciolone PhD , Andrew Winter PhD , Rahul S. Patel MD , Jafar Golzarian MD , Bulent Arslan MD

Purpose

To characterize the histologic and inflammatory changes that resulted from peripheral embolization using ethylene vinyl alcohol ([EVOH]; Onyx) in an animal model. This study also assessed the radiopacity of the Onyx after a 1-minute mixing time.

Materials and Methods

Embolization using EVOH alone or in combination with coils/plugs was performed on large-vessel, small-vessel, and very–small-vessel (3–5 mm, 1–3 mm, and <1 mm in diameter, respectively) targets in the peripheral vasculature of Yucatan miniature pigs. Multiple formulations of EVOH were used. Angiography at 1, 3, and 12 months was used to assess embolic migration and vessel occlusion. Pathological evaluations were performed to assess the biological response to Onyx-mediated embolization.

Results

Angiography demonstrated that the radiopacity of EVOH was sufficient for control during deployment in 98.2% of the procedures. Microcatheter removal was successful in all cases, and there was minimal migration of EVOH after delivery. Pathological findings indicated no significant tissue response or vessel trauma after embolization, and the occlusive material (consisting of EVOH, thrombus, and fibrotic tissue) evolved over time. The inflammatory response was minimal to mild, and vessel wall injury was observed in some cases. Complete to near-complete occlusion was achieved at every embolization site at the time of follow-up, although histologic evidence of recanalization was observed in 59.3% of the treated vessels.

Conclusions

The study demonstrated the effectiveness of EVOH as an embolic agent in the peripheral vascular system with adequate radiopacity, minimal adverse effects, and acceptable long-term histologic outcomes in a swine model.

目的：在动物模型中描述玛onyx （EVOH）外周栓塞引起的组织学和炎症变化。本研究还评估了混合时间1分钟后玛瑙的放射不透性。方法：分别对大血管、小血管和极小血管（3-5 mm、1-3 mm）进行EVOH单独或联合线圈/栓栓塞。结果：血管造影显示98.2%的手术中EVOH的放射不透性足以控制部署。所有病例均成功取出微导管，分娩后EVOH迁移最小。病理结果显示栓塞后没有明显的组织反应或血管损伤，并且闭塞物质（由EVOH、血栓和纤维化组织组成）随着时间的推移而演变。炎症反应轻微到轻微，在一些病例中观察到血管壁损伤。在随访时，每个栓塞部位都实现了完全或接近完全的闭塞，尽管在59.3%的治疗血管中观察到再通的组织学证据。结论：该研究在猪模型中证明了EVOH作为外周血管系统栓塞剂的有效性，具有足够的放射线透明度，最小的不良反应和可接受的长期组织学结果。

{"title":"Peripheral Vasculature Embolization with the Onyx Liquid Embolic System in a Swine Model","authors":"Gary P. Siskin MD , Paul J. Rochon MD , Ripal Gandhi MD , Austin Cocciolone PhD , Andrew Winter PhD , Rahul S. Patel MD , Jafar Golzarian MD , Bulent Arslan MD","doi":"10.1016/j.jvir.2025.08.032","DOIUrl":"10.1016/j.jvir.2025.08.032","url":null,"abstract":"<div><h3>Purpose</h3><div>To characterize the histologic and inflammatory changes that resulted from peripheral embolization using ethylene vinyl alcohol ([EVOH]; Onyx) in an animal model. This study also assessed the radiopacity of the Onyx after a 1-minute mixing time.</div></div><div><h3>Materials and Methods</h3><div>Embolization using EVOH alone or in combination with coils/plugs was performed on large-vessel, small-vessel, and very–small-vessel (3–5 mm, 1–3 mm, and <1 mm in diameter, respectively) targets in the peripheral vasculature of Yucatan miniature pigs. Multiple formulations of EVOH were used. Angiography at 1, 3, and 12 months was used to assess embolic migration and vessel occlusion. Pathological evaluations were performed to assess the biological response to Onyx-mediated embolization.</div></div><div><h3>Results</h3><div>Angiography demonstrated that the radiopacity of EVOH was sufficient for control during deployment in 98.2% of the procedures. Microcatheter removal was successful in all cases, and there was minimal migration of EVOH after delivery. Pathological findings indicated no significant tissue response or vessel trauma after embolization, and the occlusive material (consisting of EVOH, thrombus, and fibrotic tissue) evolved over time. The inflammatory response was minimal to mild, and vessel wall injury was observed in some cases. Complete to near-complete occlusion was achieved at every embolization site at the time of follow-up, although histologic evidence of recanalization was observed in 59.3% of the treated vessels.</div></div><div><h3>Conclusions</h3><div>The study demonstrated the effectiveness of EVOH as an embolic agent in the peripheral vascular system with adequate radiopacity, minimal adverse effects, and acceptable long-term histologic outcomes in a swine model.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107815"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Embolization of Roux-en-Y Limb Varices and Portal Vein/Rex Shunt Recanalization in Pediatric Liver Transplant Recipients with Gastrointestinal Bleeding 小儿肝移植术后消化道出血患者Roux-en-Y肢体静脉曲张栓塞及门静脉/Rex分流再通

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.011

Claudia Moya Ochoa MD , Eduardo Bravo Rius MD , Gloria González García MD , María Paz Muñoz Fernández MD , Álvaro Vega González MD , Leonardo Álvarez Aros MD

引用次数: 0

Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion 经皮肝灌注治疗葡萄膜黑色素瘤肝转移。

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Journal of Vascular and Interventional Radiology

Pub Date : 2026-01-01 DOI: 10.1016/j.jvir.2025.10.018

Siddharth A. Padia MD , Sachin Modi BSc, MBBS, FRCR, MD , Eric Wehrenberg-Klee MD , Robert D. Adamo MD , Altan Ahmed MD, MSc , Marlana Orloff MD , Hendrik J.F. Helmerhorst MD, PhD , Bartosz Chmielowski MD, PhD , Orhan S. Ozkan MD , Mark C. Burgmans MD, PhD , Gerd Grözinger MD , Robert J. Lewandowski MD , Venkatesh P. Krishnasamy MD

Uveal melanoma frequently metastasizes to the liver, with over 90% of metastatic cases involving hepatic spread. Despite systemic therapy advances, prognosis remains poor in hepatic-dominant disease. Percutaneous hepatic perfusion (PHP) with melphalan, now U.S. Food and Drug Administration (FDA)–approved via the Hepzato Kit, delivers high-dose chemotherapy directly to the liver while reducing systemic toxicity through extracorporeal filtration. This review outlines PHP’s rationale, technique, patient selection, and institutional requirements. Ideal candidates have multifocal, bilobar liver metastases and limited extrahepatic disease. PHP requires coordinated care across interventional radiology, anesthesia, perfusion, and pharmacy. Clinical data show encouraging survival and disease control with manageable hematologic toxicity and rapid recovery. Research into improved filtration, optimized dosing, and immunotherapy integration may further improve outcomes.

葡萄膜黑色素瘤（UM）经常转移到肝脏，超过90%的转移病例涉及肝脏扩散。尽管全身治疗取得进展，但肝显性疾病的预后仍然很差。经皮肝灌注（PHP）使用melphalan，目前已通过Hepzato Kit获得fda批准，可直接向肝脏提供高剂量化疗，同时通过体外过滤降低全身毒性。这篇综述概述了PHP的基本原理、技术、患者选择和机构要求。理想的候选人有多灶性、双叶性肝转移和有限的肝外疾病。PHP需要介入放射学、麻醉、灌注和药学的协调护理。临床数据显示令人鼓舞的生存和疾病控制与可控的血液毒性和快速恢复。改进过滤、优化剂量和免疫治疗整合的研究可能会进一步改善结果。

{"title":"Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion","authors":"Siddharth A. Padia MD , Sachin Modi BSc, MBBS, FRCR, MD , Eric Wehrenberg-Klee MD , Robert D. Adamo MD , Altan Ahmed MD, MSc , Marlana Orloff MD , Hendrik J.F. Helmerhorst MD, PhD , Bartosz Chmielowski MD, PhD , Orhan S. Ozkan MD , Mark C. Burgmans MD, PhD , Gerd Grözinger MD , Robert J. Lewandowski MD , Venkatesh P. Krishnasamy MD","doi":"10.1016/j.jvir.2025.10.018","DOIUrl":"10.1016/j.jvir.2025.10.018","url":null,"abstract":"<div><div>Uveal melanoma frequently metastasizes to the liver, with over 90% of metastatic cases involving hepatic spread. Despite systemic therapy advances, prognosis remains poor in hepatic-dominant disease. Percutaneous hepatic perfusion (PHP) with melphalan, now U.S. Food and Drug Administration (FDA)–approved via the Hepzato Kit, delivers high-dose chemotherapy directly to the liver while reducing systemic toxicity through extracorporeal filtration. This review outlines PHP’s rationale, technique, patient selection, and institutional requirements. Ideal candidates have multifocal, bilobar liver metastases and limited extrahepatic disease. PHP requires coordinated care across interventional radiology, anesthesia, perfusion, and pharmacy. Clinical data show encouraging survival and disease control with manageable hematologic toxicity and rapid recovery. Research into improved filtration, optimized dosing, and immunotherapy integration may further improve outcomes.</div></div>","PeriodicalId":49962,"journal":{"name":"Journal of Vascular and Interventional Radiology","volume":"37 1","pages":"Article 107887"},"PeriodicalIF":2.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145370520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Vascular and Interventional Radiology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀